Generation of recombinant antibodies against toxins and viruses by phage display for diagnostics and therapy

Advances in Experimental Medicine and Biology

Volumn 917, Issue , 2016, Pages 55-76

  Unkauf, Tobias ^a   Miethe, Sebastian ^a   Fühner, Viola ^a   Schirrmann, Thomas ^a,b   Frenzel, André ^a,b   Hust, Michael ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b YUMAB GmbH   (Germany)

Author keywords

Antibody; Antibody engineering; Pathogen; Phage display; scFv; Therapy; Toxins; Viruses

Indexed keywords

BACTERIAL TOXIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; SMALLPOX VACCINE; TOXIN ANTIBODY; VIRUS ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; BOTULISM; DENGUE VIRUS; DIAGNOSTIC TEST; DNA VIRUS; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENE LIBRARY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RNA VIRUS INFECTION; SMALLPOX; VACCINATION; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRUS NEUTRALIZATION; WESTERN EQUINE ENCEPHALITIS VIRUS;

EID: 85019201536     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-32805-8_4     Document Type: Chapter

References (135)

1. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147-1157. doi:10.1038/nbt1137
2. Alonso-Ruiz A, Pijoan JI, Ansuategui E et al (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9: 52. doi:1471-2474-9-52
3. Amersdorfer P, Wong C, Chen S et al (1997) Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun 65:3743-3752
4. Amersdorfer P, Wong C, Smith T et al (2002) Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 20:1640-1648. doi:10.1016/S0264-410X(01)00482-0
5. Amaro I, Riaño-Umbarila L, Becerril B, Possani LD (2011) Isolation and characterization of a human antibody fragment specific for Ts1 toxin from Tityus serrulatus scorpion. Immunol Lett 139:73-79. doi:10.1016/j.imlet.2011.05.002
6. Anderson GP, Liu JL, Hale ML et al (2008) Development of antiricin single domain antibodies toward detection and therapeutic reagents. Anal Chem 80:9604-9611. doi:10.1021/ ac8019398
7. Arakawa M, Yamashiro T, Uechi G et al (2007) Construction of human Fab (gamma1/kappa) library and identification of human monoclonal Fab possessing neutralizing potency against Japanese encephalitis virus. Microbiol Immunol 51:617-625
8. Arnon SS, Schechter R, Inglesby TV et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA J Am Med Assoc 285:1059-1070
9. Avnir Y, Tallarico AS, Zhu Q et al (2014) Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog 10:e1004103. doi:10.1371/journal.ppat.1004103
10. Bakherad H, Mousavi Gargari SL, Rasooli I et al (2013) In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Mol Biotechnol 55:159-167. doi:10.1007/s12033-013-9669-1
11. Barash JR, Arnon SS (2014) A novel strain of clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 209:183-191. doi:10.1093/infdis/jit449
12. Barbas CF, Kang AS, Lerner RA, Benkovic SJ (1991) Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A 88:7978-7982. doi:1896445
13. Berhanu A, Wilson RL, Kirkwood-Watts DL et al (2008) Vaccination of BALB/c mice with escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 82:3517-3529. doi:10.1128/JVI.01854-07
14. Breitling F, Dübel S, Seehaus T et al (1991) A surface expression vector for antibody screening. Gene 104:147-153
15. Cabezas S, Rojas G, Pavon A et al (2008) Selection of phage-displayed human antibody fragments on dengue virus particles captured by a monoclonal antibody: application to the four serotypes. J Virol Methods 147:235-243. doi:10.1016/j.jviromet.2007.09.001
16. Chahboun S, Hust M, Liu Y et al (2011) Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol 11:113. doi:10.1186/1472-6750-11-113
17. Chassagne S, Laffly E, Drouet E et al (2004) A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol 41:539-546. doi:10.1016/j.molimm.2004.03.040
18. Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7:622-632. doi:nri2134
19. Chen Z, Chumakov K, Dragunsky E et al (2011) Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J Virol 85:4354-4362. doi:10.1128/JVI.02553-10
20. Chen Z, Earl P, Americo J et al (2006) Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A 103:1882-1887. doi:10.1073/pnas.0510598103
21. Chulanetra M, Bangphoomi K, Sookrung N et al (2012) Human ScFv that block sodium ion channel activity of tetrodotoxin. Toxicon 59:272-282. doi:10.1016/j.toxicon.2011.11.012
22. Clackson T, Hoogenboom HR, Griffiths AD, Winter G (1991) Making antibody fragments using phage display libraries. Nature 352:624-628. doi:1907718
23. Cole SP, Campling BG, Atlaw T et al (1984) Human monoclonal antibodies. Mol Cell Biochem 62:109-120
24. Colwill K, Gräslund S (2011) A roadmap to generate renewable protein binders to the human proteome. Nat Methods 8:551-558. doi:10.1038/nmeth.1607
25. Conway JO, Sherwood LJ, Collazo MT et al (2010) Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS One 5:e8818. doi:10.1371/journal.pone.0008818
26. Courtenay-Luck NS, Epenetos AA, Moore R et al (1986) Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46:6489-6493. doi:2430699
27. Daffis S, Kontermann RE, Korimbocus J et al (2005) Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology 337:262-272. doi:10.1016/j. virol.2005.04.031
28. De Alwis R, Smith SA, Olivarez NP et al (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109:7439-7444. doi:10.1073/pnas.1200566109
29. De Haard HJ, van Neer N, Reurs A et al (1999) A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 274:18218-18230. doi:10373423
30. Dübel S, Stoevesandt O, Taussig MJ, Hust M (2010) Generating recombinant antibodies to the complete human proteome. Trends Biotechnol 28:333-339. doi: 10.1016/j. tibtech.2010.05.001
31. Earl PL, Americo JL, Wyatt LS et al (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182-185. doi:10.1038/ nature02331
32. Endo Y, Mitsui K, Motizuki M, Tsurugi K (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem 262:5908-5912
33. Fatima A, Wang H, Kang K et al (2014) Development of VHH antibodies against dengue virus type 2 NS1 and comparison with monoclonal antibodies for use in immunological diagnosis. PLoS One 9:e95263. doi:10.1371/journal.pone.0095263
34. Fishwild DM, O’Donnell SL, Bengoechea T et al (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 14:845-851. doi:9631008
35. Frenzel A, Kügler J, Wilke S et al (2014) Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol 1060:215-243. doi:10.1007/978-1-62703-586-6_12
36. Froude JW, Stiles B, Pelat T, Thullier P (2011) Antibodies for biodefense. MAbs 3:517-527. doi:10.4161/mabs.3.6.17621
37. Funayama JC, Pucca MB, Roncolato EC et al (2012) Production of human antibody fragments binding to melittin and phospholipase A2 in Africanised bee venom: minimising venom toxicity. Basic Clin Pharmacol Toxicol 110:290-297. doi:10.1111/j.1742-7843.2011.00821.x
38. Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86-94
39. Goncalvez AP, Chien C-H, Tubthong K et al (2008) Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol 82:7009-7021. doi:10.1128/JVI.00291-08
40. Goodchild SA, Dooley H, Schoepp RJ et al (2011) Isolation and characterisation of Ebolavirus-specific recombinant antibody fragments from murine and shark immune libraries. Mol Immunol 48:2027-2037. doi:10.1016/j.molimm.2011.06.437
41. Gould LH, Sui J, Foellmer H et al (2005) Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 79:14606-14613. doi:10.1128/JVI.79.23.14606-14613.2005
42. Hammond PW (2010) Accessing the human repertoire for broadly neutralizing HIV antibodies. MAbs 2:157-164
43. Henderson DA, Inglesby TV, Bartlett JG et al (1999) Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281:2127-2137
44. Higo-Moriguchi K, Shirato H, Someya Y et al (2014) Isolation of cross-reactive human monoclonal antibodies that prevent binding of human noroviruses to histo-blood group antigens. J Med Virol 86:558-567. doi:10.1002/jmv.23734
45. Hoet RM, Cohen EH, Kent RB et al (2005) Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 23:344-348. doi:nbt1067
46. Holt LJ, Herring C, Jespers LS et al (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21:484-490
47. Houimel M (2014) The analysis of VH and VL genes repertoires of Fab library built from peripheral B cells of human rabies virus vaccinated donors. Hum Immunol 75:745-755. doi:10.1016/j.humimm.2014.05.005
48. Hülseweh B, Rülker T, Pelat T et al (2014) Human-like antibodies neutralizing Western equine encephalitis virus. MAbs 6:717-726. doi:10.4161/mabs.28170
49. Hunt AR, Frederickson S, Maruyama T et al (2010) The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl Trop Dis 4:e739. doi:10.1371/journal.pntd.0000739
50. Hussack G, Arbabi-Ghahroudi M, van Faassen H et al (2011) Neutralization of clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem 286:8961-8976. doi:10.1074/jbc.M110.198754
51. Hust M, Jostock T, Menzel C et al (2007) Single chain Fab (scFab) fragment. BMC Biotechnol 7:14
52. Hust M, Meyer T, Voedisch B et al (2011) A human scFv antibody generation pipeline for proteome research. J Biotechnol 152:159-170. doi:10.1016/j.jbiotec.2010.09.945
53. Hu W-G, Jager S, Chau D et al (2010) Generation of a recombinant full-length human antibody binding to botulinum neurotoxin A. Appl Biochem Biotechnol 160:1206-1216. doi:10.1007/s12010-009-8657-1
54. Indrawattana N, Sookrung N, Kulkeaw K et al (2010) Human monoclonal ScFv that inhibits cellular entry and metalloprotease activity of tetanus neurotoxin. Asian Pac J Allergy Immunol 28:85-93
55. Inglesby TV, O’Toole T, Henderson DA et al (2002) Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA J Am Med Assoc 287:2236-2252
56. Jäger V, Büssow K, Wagner A et al (2013) High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 13:52. doi:10.1186/1472-6750-13-52
57. Jakobovits A (1995) Production of fully human antibodies by transgenic mice. Curr Opin Biotechnol 6:561-566. doi:7579668
58. Johnson KM, Martin DH (1974) Venezuelan equine encephalitis. Adv Vet Sci Comp Med 18:79-116
59. Kang X, Yang B-A, Hu Y et al (2006) Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display. Clin Vaccine Immunol CVI 13:953-957. doi:10.1128/CVI.00037-06
60. Kirsch GE, Skattebøl A, Possani LD, Brown AM (1989) Modification of Na channel gating by an alpha scorpion toxin from Tityus serrulatus. J Gen Physiol 93:67-83
61. Kirsch M, Hülseweh B, Nacke C et al (2008) Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol 8:66. doi:1472-6750-8-66
62. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497. doi:1172191
63. Kramer RA, Marissen WE, Goudsmit J et al (2005) The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 35:2131-2145. doi:10.1002/eji.200526134
64. Kulkeaw K, Sakolvaree Y, Srimanote P et al (2009) Human monoclonal ScFv neutralize lethal Thai cobra, Naja kaouthia, neurotoxin. J Proteomics 72:270-282. doi:10.1016/j. jprot.2008.12.007
65. Kummerfeldt CE (2014) Raxibacumab: potential role in the treatment of inhalational anthrax. Infect Drug Resist 7:101-109. doi:10.2147/IDR.S47305
66. Larkin EA, Stiles BG, Ulrich RG (2010) Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One 5:e13253. doi:10.1371/journal. pone.0013253
67. Lim APC, Chan CEZ, Wong SKK et al (2008) Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virol J. doi:10.1186/1743-422X-5-130
68. Liu H, Zheng X, Shi X et al (2014) Selection and characterization of single-chain recombinant antibodies against infectious haematopoietic necrosis virus from mouse phage display library. J Virol Methods 205C:61-67. doi:10.1016/j.jviromet.2014.04.008
69. Liu S, Moayeri M, Leppla SH (2014) Anthrax lethal and edema toxins in anthrax pathogenesis. Trends Microbiol 22:317-325. doi:10.1016/j.tim.2014.02.012
70. Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. Int Rev Immunol 13:65-93. doi:7494109
71. Malley R, DeVincenzo J, Ramilo O et al (1998) Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 178:1555-1561
72. Maneewatch S, Thanongsaksrikul J, Songserm T et al (2009) Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza A virus subtype H5N1. Antivir Ther 14:221-230
73. Maruyama T, Parren PW, Sanchez A et al (1999) Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 179(Suppl 1):S235-S239. doi:10.1086/514280
74. Maruyama T, Rodriguez LL, Jahrling PB et al (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73:6024-6030
75. Mazumdar S (2009) Raxibacumab. MAbs 1:531-538
76. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552-554
77. Men R, Yamashiro T, Goncalvez AP et al (2004) Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus. J Virol 78:4665-4674
78. Meyer T, Stratmann-Selke J, Meens J et al (2011) Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium. Vet Microbiol 147:162-169. doi:10.1016/j. vetmic.2010.06.023
79. Miethe S, Rasetti-Escargueil C, Liu Y et al (2014) Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs 6:446-459. doi:10.4161/mabs.27773
80. Mohammadzadeh S, Rajabibazl M, Fourozandeh M et al (2014) Production of recombinant scFv against p24 of human immunodeficiency virus type 1 by phage display technology. Monoclon Antib Immunodiagn Immunother 33:28-33. doi:10.1089/mab.2013.0059
81. Moreland NJ, Susanto P, Lim E et al (2012) Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries. Int J Mol Sci 13:2618-2635. doi:10.3390/ijms13032618
82. Moreland NJ, Tay MYF, Lim E et al (2010) High affinity human antibody fragments to dengue virus non-structural protein 3. PLoS Negl Trop Dis 4:e881. doi:10.1371/journal. pntd.0000881
83. Muyldermans S (2001) Single domain camel antibodies: current status. J Biotechnol 74:277-302
84. Muyldermans S, Baral TN, Retamozzo VC et al (2009) Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol 128:178-183. doi:10.1016/j. vetimm.2008.10.299
85. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767-774. doi:10.1038/nrd3229
86. Neri P, Shigemori N, Hamada-Tsutsumi S et al (2011) Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library. Vaccine 29:5340-5346. doi:10.1016/j.vaccine.2011.05.093
87. Nicolson GL, Lacorbiere M, Hunter TR (1975) Mechanism of cell entry and toxicity of an affinity-purified lectin from Ricinus communis and its differential effects on normal and virus-transformed fibroblasts. Cancer Res 35:144-155
88. Nuttall SD, Humberstone KS, Krishnan UV et al (2004) Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA 1. Proteins 55:187-197. doi:10.1002/prot.20005
89. Nuttall SD, Krishnan UV, Hattarki M et al (2001) Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol 38:313-326
90. Ono HK, Omoe K, Imanishi K et al (2008) Identification and characterization of two novel staphylococcal enterotoxins, types S and T. Infect Immun 76:4999-5005. doi: 10.1128/ IAI.00045-08
91. Oswald WB, Geisbert TW, Davis KJ et al (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3:e9. doi:10.1371/journal. ppat.0030009
92. Parmley SF, Smith GP (1988) Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73:305-318
93. Parren PWHI, Geisbert TW, Maruyama T et al (2002) Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76:6408-6412
94. Pauza ME, Rehmann JA, LeBien TW (1993) Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains. J Exp Med 178:139-149
95. Peeters M, Price T, Van Laethem J-L (2009) Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 14:29-39. doi:10.1634/theoncologist.2008-0167
96. Pelat T, Hust M, Hale M et al (2009) Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 9:60. doi:10.1186/1472-6750-9-60
97. Pelat T, Hust M, Laffly E et al (2007) High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 51:2758-2764
98. Pereira SS, Moreira-Dill LS, Morais MSS et al (2014) Novel camelid antibody fragments targeting recombinant nucleoprotein of Araucaria hantavirus: a prototype for an early diagnosis of hantavirus pulmonary syndrome. PLoS One 9:e108067. doi:10.1371/journal. pone.0108067
99. Possani LD, Martin BM, Svendsen I et al (1985) Scorpion toxins from Centruroides noxius and Tityus serrulatus. Primary structures and sequence comparison by metric analysis. Biochem J 229:739-750
100. Ray K, Embleton MJ, Jailkhani BL et al (2001) Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1. Clin Exp Immunol 125:94-101
101. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413-415. doi:10.4161/mabs.19931
102. Reichert JM (2013) Which are the antibodies to watch in 2013? MAbs 5:1-4. doi:10.4161/ mabs.22976
103. Riaño-Umbarila L, Juárez-González VR, Olamendi-Portugal T et al (2005) A strategy for the generation of specific human antibodies by directed evolution and phage display. An example of a single-chain antibody fragment that neutralizes a major component of scorpion venom. FEBS J 272:2591-2601. doi:10.1111/j.1742-4658.2005.04687.x
104. Roncolato EC, Pucca MB, Funayama JC et al (2013) Human antibody fragments specific for Bothrops jararacussu venom reduce the toxicity of other Bothrops sp. venoms. J Immunotoxicol 10:160-168. doi:10.3109/1547691X.2012.703253
105. Rülker T, Voß L, Thullier P et al (2012) Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One 7:e37242. doi:10.1371/journal.pone.0037242
106. Saokaew N, Poungpair O, Panya A et al (2014) Human monoclonal single-chain antibodies specific to dengue virus envelope protein. Lett Appl Microbiol 58:270-277. doi:10.1111/ lam.12186
107. Schofield DJ, Pope AR, Clementel V et al (2007) Application of phage display to high throughput antibody generation and characterization. Genome Biol 8:R254. doi: 10.1186/ gb-2007-8-11-r254
108. Schofield DJ, Satterfield W, Emerson SU, Purcell RH (2002) Four chimpanzee monoclonal antibodies isolated by phage display neutralize hepatitis a virus. Virology 292:127-136. doi:10.1006/viro.2001.1252
109. Shingarova LN, Tikunova NV, Iun TE et al (2007) Recombinant full-size human antibody to Ebola virus. Bioorg Khim 33:598-605
110. Singh PK, Agrawal R, Kamboj DV et al (2010) Construction of a single-chain variable-fragment antibody against the superantigen Staphylococcal enterotoxin B. Appl Environ Microbiol 76:8184-8191. doi:10.1128/AEM.01441-10
111. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317
112. Songsivilai S, Dharakul T (1998) Genetically engineered single-chain Fvs of human immunoglobulin against hepatitis C virus nucleocapsid protein derived from universal phage display library. Asian Pac J Allergy Immunol 16:31-41
113. Sui J, Hwang WC, Perez S et al (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265-273. doi:10.1038/nsmb.1566
114. Sui J, Li W, Murakami A et al (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 101:2536-2541
115. Sun L, Chen Z, Yu L et al (2012) Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein. Appl Microbiol Biotechnol 96:357-366. doi:10.1007/s00253-012-4171-4
116. Sun L, Lu X, Li C et al (2009) Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4:e5476. doi:10.1371/journal.pone.0005476
117. Thanongsaksrikul J, Srimanote P, Maneewatch S et al (2010) A V H H that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J Biol Chem 285:9657-9666. doi:10.1074/jbc.M109.073163
118. Thomas DY, Jarraud S, Lemercier B et al (2006) Staphylococcal enterotoxin-like toxins U2 and V, two new staphylococcal superantigens arising from recombination within the enterotoxin gene cluster. Infect Immun 74:4724-4734. doi:10.1128/IAI.00132-06
119. Throsby M, van den Brink E, Jongeneelen M et al (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3:e3942. doi:10.1371/journal.pone.0003942
120. Tikunova N, Dubrovskaya V, Morozova V et al (2012) The neutralizing human recombinant antibodies to pathogenic Orthopoxviruses derived from a phage display immune library. Virus Res 163:141-150. doi:10.1016/j.virusres.2011.09.008
121. Tremblay JM, Mukherjee J, Leysath CE et al (2013) A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun 81:4592-4603. doi:10.1128/IAI.01033-13
122. Trott M, Weiβ S, Antoni S et al (2014) Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3-and a trimer-specific gp41 antibody. PLoS One 9:e97478. doi:10.1371/journal.pone.0097478
123. Urushibata Y, Itoh K, Ohshima M, Seto Y (2010) Generation of Fab fragment-like molecular recognition proteins against staphylococcal enterotoxin B by phage display technology. Clin Vaccine Immunol CVI 17:1708-1717. doi:10.1128/CVI.00229-10
124. Vaughan TJ, Williams AJ, Pritchard K et al (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14:309-314. doi:9630891
125. Velappan N, Martinez JS, Valero R et al (2007) Selection and characterization of scFv antibodies against the Sin Nombre hantavirus nucleocapsid protein. J Immunol Methods 321:60-69. doi:10.1016/j.jim.2007.01.011
126. Von Behring E, Kitasato S (1890) Über das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenzeitschrift 16:1113-1114
127. Wang Y, Zhang X, Zhang C et al (2012) Isolation of single chain variable fragment (scFv) specific for Cry1C toxin from human single fold scFv libraries. Toxicon 60:1290-1297. doi:10.1016/j.toxicon.2012.08.014
128. Weaver SC, Ferro C, Barrera R et al (2004) Venezuelan equine encephalitis. Annu Rev Entomol 49:141-174. doi:10.1146/annurev.ento.49.061802.123422
129. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433-455. doi:8011287
130. Winter G, Milstein C (1991) Man-made antibodies. Nature 349:293-299. doi:1987490
131. Wu J, Zeng X-Q, Zhang H-B et al (2014) Novel phage display-derived H5N1-specific scFvs with potential use in rapid avian flu diagnosis. J Microbiol Biotechnol 24:704-713
132. Wyrzucki A, Dreyfus C, Kohler I et al (2014) Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody. J Virol 88:7083-7092. doi:10.1128/JVI.00178-14
133. Yang Z, Schmidt D, Liu W et al (2014) A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 210:964-972. doi:10.1093/infdis/jiu196
134. Zhao Y, Moreland NJ, Tay MYF et al (2014) Identification and molecular characterization of human antibody fragments specific for dengue NS5 protein. Virus Res 179:225-230. doi:10.1016/j.virusres.2013.11.010
135. Zhu Z, Dimitrov AS, Bossart KN et al (2006) Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 80:891-899. doi: 10.1128/ JVI.80.2.891-899.2006